Press Releases

Press Releases

Date Title & Summary Additional Formats
06/15/17
Cidara Therapeutics to Participate in the 2017 BIO International Convention
Panel Discussion Will Highlight Urgent Needs and Opportunities in Antifungal Development SAN DIEGO --(BUSINESS WIRE)--Jun. 15, 2017-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein ,
05/30/17
Cidara Therapeutics Announces Presentations at ASM Microbe 2017 and the 22nd Congress of the European Hematology Association
Data Highlight Expanded Utility of CD101 for Potential Treatment and Prevention of Serious Fungal Infections SAN DIEGO --(BUSINESS WIRE)--May 30, 2017-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that
05/10/17
Cidara Provides Corporate Update and Reports First Quarter 2017 Financial Results
SAN DIEGO , May 10, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended March 31, 2017 and provided an update on its corporate activities and
04/25/17
Cidara Therapeutics Announces Promotion of Taylor Sandison, M.D., M.P.H., to Chief Medical Officer
SAN DIEGO --(BUSINESS WIRE)--Apr. 25, 2017-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Taylor Sandison , M.D., M.P.H., has been named chief medical officer (CMO) of the company. Dr.
04/17/17
Cidara Therapeutics to Present Data on Novel Antifungal CD101 and Cloudbreak Antibacterial Immunotherapy at ECCMID and SID Annual Meetings
SAN DIEGO --(BUSINESS WIRE)--Apr. 17, 2017-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from nonclinical studies of its novel echinocandin antifungal CD101 and its Cloudbreak TM antibacterial
03/30/17
Cidara Therapeutics Awarded $6.9 Million Grant from CARB-X to Advance Development of its First CloudbreakTM Antibiotic Immunotherapy
CARB-X Funding to Advance Novel First-in-Class Bispecific Immunotherapy to Fight Multi-drug Resistant Bacterial Infections SAN DIEGO --(BUSINESS WIRE)--Mar. 30, 2017-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today
03/29/17
Cidara Therapeutics to Host Investor Day on April 6, 2017
SAN DIEGO , March 29, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, will host an Investor Day on Thursday, April 6, 2017 , from 8:30 a.m. to 11:30 a.m. EDT ( 5:30 a.m. to 8:30 a.m.
03/15/17
Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
SAN DIEGO , March 15, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months and full year ended December 31, 2016 and provided an update on its
02/21/17
Cidara Therapeutics Reports Unfavorable Results of Phase 2 RADIANT Trial of CD101 Topical in VVC
Further Development of CD101 Topical for VVC to be discontinued CD101 IV development program in candidemia and invasive candidiasis (including Phase 2 STRIVE trial) continuing and remains on track Company to Host Conference Call Today at 5:30 a.m. PT SAN DIEGO , Feb.
01/04/17
Cidara Therapeutics Completes Enrollment in Phase 2 RADIANT Trial Evaluating Novel Antifungal CD101 Topical in Vulvovaginal Candidiasis
Topline Data Expected in First Quarter 2017 SAN DIEGO --(BUSINESS WIRE)--Jan. 4, 2017-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the completion of patient enrollment in the RADIANT trial, a Phase 2